High doses of Everolimus induce transcriptomic changes in bronchial epithelial cells from cystic fibrosis patients

ABSTRACT: BACKGROUND: At the moment, lung transplantation remains the best therapeutic option to ensure a better survival rate of cystic fibrosis (CF) patients, but, unfortunately, immunosuppressive therapies, often employed at high dosages to avoid acute rejection and a rapid pulmonary loss, may induce severe complications. In particular, patients treated with high dose of mammalian target of rapamycin inhibitors (mTOR-Is) may experience pulmonary fibrosis-associated adverse effects (including BOOP). Although epithelial to mesenchymal transition (EMT) of airway cells has a central role in this process, the complete biological machinery involved is not completely clarified. METHODS: In order to improve our knowledge on this process, primary bronchial epithelial cell cultures carrying F508del (BE91/3

ORGANISM(S): Homo sapiens

SUBMITTER: Fabio Sallustio 

PROVIDER: E-MTAB-8123 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress